Overview

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.

Status:
Completed
Trial end date:
2009-07-20
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses of GSK962040.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Motilin